Sfoglia per Autore
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY
2007 Guarneri, V.; Frassoldati, A.; Cagossi, K.; Bottini, A.; Cavanna, L.; Michelotti, A.; Jovic, G.; Piacentini, F.; Oliva, C.; Conte, Pf.
Osteonecrosis of the jaw: Long-term follow-up shows variable rate of healing
2007 M. I., Hu; A. O., Hoff; B. B., Toth; K., Altundag; Guarneri, Valentina; J., Cui; G. N., Hortobagyi; R. F., Gagel
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
2007 Thomas, E; Tabernero, J; Fornier, M; Conte, Pierfranco; Fumoleau, P; Lluch, A; Vahdat, Lt; Bunnell, Ca; Burris, Ha; Viens, P; Baselga, J; Rivera, E; Guarneri, Valentina; Poulart, V; Klimovsky, J; Lebwohl, D; Martin, M.
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden
2007 Cristofanilli, M; Broglio, Kr; Guarneri, Valentina; Jackson, S; Fritsche, Ha; Islam, R; Dawood, S; Reuben, Jm; Kau, Sw; Lara, Jm; Krishnamurthy, S; Ueno, Nt; Hortobagyi, Gn; Valero, V.
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
2007 CONTE, Pierfranco; GUARNERI, Valentina; BENGALA, C.
Controversies of chemotherapy for the treatment of metastatic breast cancer.
2007 Conte, Pierfranco; Bengala, C; Guarneri, Valentina
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability
2007 Frassoldati, A; Guarneri, Valentina; Cagossi, K.; Bottini, A; Cavanna, L; Jovic, Gordana; Piacentini, Federico; Oliva, C; Conte, Pierfranco
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER
2007 Guarneri, V.; Piacentini, F.; Frassoldati, A.; Ficarra, G.; Jovic, G.; Pugliesi, F.; Michelotti, A.; Bisagni, G.; Berardi, R.; Conte, Pf.
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB
2007 Giovannelli, S.; Bengala, C.; Grisolia, D.; Frassoldati, A.; Piacentini, F.; Guarneri, V.; Sabbatini, R.; Ferrari, A.; Conte, Pf.
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives
2007 Guarneri, Valentina; A., Frassoldati; Giovannelli, Simona; F., Borghi; Conte, Pierfranco
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer
2007 Guarneri, Valentina; Frassoldati, A; Piacentini, Federico; Cagossi, K; Cavanna, L; Michelotti, A; Jovic, Gordana; Giovannelli, Simona; Ficarra, G; Oliva, C; Conte, Pierfranco
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS
2008 Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Piacentini, F.; Barbieri, E.; Dieci, Mv.; Jovic, G.; Conte, Pf.
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer
2008 Guarneri, Valentina; Pecchi, Annarita; Torricelli, Pietro; Piacentini, Federico; A., Frassoldati; C., Mauri; R., Battista; B., Canossi; D'Amico, Roberto; Conte, Pierfranco
Progress in the treatment of Early and Advanced Breast Cancer
2008 Guarneri, Valentina; Piacentini, Federico; Conte, Pierfranco
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB)
2008 Frassoldati, A; Guarneri, Valentina; Piacentini, Federico; Jovic, Gordana; Giovannelli, Simona; Oliva, C; Conte, Pierfranco
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data
2008 Guarneri, Valentina; A., Frassoldati; K., Cagossi; A., Bottini; A., Michelotti; L., Cavanna; Jovic, Gordana; Piacentini, Federico; C., Oliva; Conte, Pierfranco
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study
2008 A., Frassoldati; Guarneri, Valentina; A., Bottini; K., Cagossi; L., Cavanna; G., Bisagni; G., Jovic; Piacentini, Federico; C., Oliva; Conte, Pierfranco
Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates
2008 Hoff, Ao; Toth, B; Altundag, K; Johnson, M; Warneke, C; Nooka, A; Sayegh, G; Guarneri, Valentina; Desrouleaux, K; Cui, J; Adamus, A; GAGEL RF AND HORTOBAGYI, Gn
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
2008 Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE
2008 Piacentini, F.; Guarneri, V.; Ficarra, G.; Frassoldati, A.; D’Amico, R.; Giovannelli, S.; Maiorana, A.; Conte, Pf.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY | 1-gen-2007 | Guarneri, V.; Frassoldati, A.; Cagossi, K.; Bottini, A.; Cavanna, L.; Michelotti, A.; Jovic, G.; Piacentini, F.; Oliva, C.; Conte, Pf. | |
Osteonecrosis of the jaw: Long-term follow-up shows variable rate of healing | 1-gen-2007 | M. I., Hu; A. O., Hoff; B. B., Toth; K., Altundag; Guarneri, Valentina; J., Cui; G. N., Hortobagyi; R. F., Gagel | |
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer | 1-gen-2007 | Thomas, E; Tabernero, J; Fornier, M; Conte, Pierfranco; Fumoleau, P; Lluch, A; Vahdat, Lt; Bunnell, Ca; Burris, Ha; Viens, P; Baselga, J; Rivera, E; Guarneri, Valentina; Poulart, V; Klimovsky, J; Lebwohl, D; Martin, M. | |
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden | 1-gen-2007 | Cristofanilli, M; Broglio, Kr; Guarneri, Valentina; Jackson, S; Fritsche, Ha; Islam, R; Dawood, S; Reuben, Jm; Kau, Sw; Lara, Jm; Krishnamurthy, S; Ueno, Nt; Hortobagyi, Gn; Valero, V. | |
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. | 1-gen-2007 | CONTE, Pierfranco; GUARNERI, Valentina; BENGALA, C. | |
Controversies of chemotherapy for the treatment of metastatic breast cancer. | 1-gen-2007 | Conte, Pierfranco; Bengala, C; Guarneri, Valentina | |
LET-LOB: preoperative letrozole plus lapatinib or placebo in hormone-receptor positive HER2 negative operable breats cancer. Preliminary report of activity and cardiac tolerability | 1-gen-2007 | Frassoldati, A; Guarneri, Valentina; Cagossi, K.; Bottini, A; Cavanna, L; Jovic, Gordana; Piacentini, Federico; Oliva, C; Conte, Pierfranco | |
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER | 1-gen-2007 | Guarneri, V.; Piacentini, F.; Frassoldati, A.; Ficarra, G.; Jovic, G.; Pugliesi, F.; Michelotti, A.; Bisagni, G.; Berardi, R.; Conte, Pf. | |
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB | 1-gen-2007 | Giovannelli, S.; Bengala, C.; Grisolia, D.; Frassoldati, A.; Piacentini, F.; Guarneri, V.; Sabbatini, R.; Ferrari, A.; Conte, Pf. | |
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives | 1-gen-2007 | Guarneri, Valentina; A., Frassoldati; Giovannelli, Simona; F., Borghi; Conte, Pierfranco | |
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer | 1-gen-2007 | Guarneri, Valentina; Frassoldati, A; Piacentini, Federico; Cagossi, K; Cavanna, L; Michelotti, A; Jovic, Gordana; Giovannelli, Simona; Ficarra, G; Oliva, C; Conte, Pierfranco | |
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS | 1-gen-2008 | Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Piacentini, F.; Barbieri, E.; Dieci, Mv.; Jovic, G.; Conte, Pf. | |
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer | 1-gen-2008 | Guarneri, Valentina; Pecchi, Annarita; Torricelli, Pietro; Piacentini, Federico; A., Frassoldati; C., Mauri; R., Battista; B., Canossi; D'Amico, Roberto; Conte, Pierfranco | |
Progress in the treatment of Early and Advanced Breast Cancer | 1-gen-2008 | Guarneri, Valentina; Piacentini, Federico; Conte, Pierfranco | |
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) | 1-gen-2008 | Frassoldati, A; Guarneri, Valentina; Piacentini, Federico; Jovic, Gordana; Giovannelli, Simona; Oliva, C; Conte, Pierfranco | |
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data | 1-gen-2008 | Guarneri, Valentina; A., Frassoldati; K., Cagossi; A., Bottini; A., Michelotti; L., Cavanna; Jovic, Gordana; Piacentini, Federico; C., Oliva; Conte, Pierfranco | |
Lapatinib or placebo plus letrozole as preoperative treatment of hormone receptor-positive HER2-negative operable breast cancer. Preliminary report of safety and activity of the double-blind randomized phase IIb LET-LOB study | 1-gen-2008 | A., Frassoldati; Guarneri, Valentina; A., Bottini; K., Cagossi; L., Cavanna; G., Bisagni; G., Jovic; Piacentini, Federico; C., Oliva; Conte, Pierfranco | |
Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates | 1-gen-2008 | Hoff, Ao; Toth, B; Altundag, K; Johnson, M; Warneke, C; Nooka, A; Sayegh, G; Guarneri, Valentina; Desrouleaux, K; Cui, J; Adamus, A; GAGEL RF AND HORTOBAGYI, Gn | |
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy | 1-gen-2008 | Guarneri, Valentina; Piacentini, Federico; A., Frassoldati; G., Ficarra; D'Amico, Roberto; Giovannelli, Simona; Conte, Pierfranco | |
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE | 1-gen-2008 | Piacentini, F.; Guarneri, V.; Ficarra, G.; Frassoldati, A.; D’Amico, R.; Giovannelli, S.; Maiorana, A.; Conte, Pf. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile